Table 2.
Characteristics of study participants in the clinical evaluation study.
| Disease group | Gender (m/f) | Age (years) | Afamin (mg/L) | CRP (mg/dL) | PCT (ng/mL) | IL-6 (pg/mL) | eGFR (mL/min/1.73 m2) | Albumin (g/dL) | BNP (pg/mL) |
|---|---|---|---|---|---|---|---|---|---|
| Controls (n = 22) | 12/10 | 38 (22–59) | 63 (50–101) | 0.1 (0.1–1.0) | 0.1 (0.1–0.2) | 2.0 (2.0–14) | > 90 (> 90–> 90) | 4.5 (3.9–5.0) | 17 (10–95) |
| HF (n = 15) | 11/4 | 72 (57–85) | 51 (36–89)** | 0.6 (0.1–1.0) | 0.1 (0.1–0.4) | 4.6 (2.0–15) | > 90 (81–> 90) | 3.8 (2.5–6.8) | 880 (519–3109) |
| Pneumonia (n = 15) | 13/2 | 57 (25–84) | 26 (11–65)*** | 14 (2.8–29) | 0.2 (0.1–2.8) | 48 (7–245) | > 90 (81–> 90) | 3.0 (2.2–4.0) | 66 (17–96) |
| COPD (n = 15) | 14/1 | 63 (51–82) | 72 (8–118)‡ | 0.3 (0.1–18) | 0.1 (0.1–0.4) | 2.0 (2.0–16) | > 90 (85–> 90) | 4.0 (3.6–4.6) | 48 (10–91) |
| HF + Pneum. (n = 15) | 12/3 | 80 (55–96) | 25 (11–49)*** | 8.4 (5.8–30) | 0.1 (0.1–2.2) | 43 (10–1088) | 87 (80–> 90) | 3.1 (1.9–4.5) | 864 (539–4793) |
| Renal disease (n = 15) | 12/3 | 74 (55–83) | 56 (29–89)‡ | 0.1 (0.1–1.0) | 0.1 (0.1–0.4) | 2.1 (2.0–10) | 26 (9–52) | 3.8 (3.2–4.6) | 51 (30–96) |
| Sepsis (n = 15) | 9/6 | 70 (35–83) | 24 (4–55)*** | 25 (7.6–35) | 32 (7.0–280) | 1132 (112–65500) | 44 (11–> 90) | 2.1 (1.4–3.4) | 697 (37–2575) |
Data are presented as number or median (range). Difference in afamin concentrations for the control group vs. each of the disease groups (Mann–Whitney U test, not corrected for multiple comparisons): **p = 0.001, ***p < 0.001, ‡not significant.